Dublin, July 03, 2024 (GLOBE NEWSWIRE) — The “Asia-Pacific Clinical Biomarkers Market – Analysis and Forecast, 2023-2033” report has been added to ResearchAndMarkets.com’s offering.
The Asia-Pacific clinical biomarkers market was valued at $3.28 billion in 2023 and is expected to reach $7.95 billion by 2033, growing at a CAGR of 9.27% between 2023 and 2033. Clinical biomarkers are quantifiable biological parameters that aid in understanding the progression and early diagnosis of diseases. These biomarkers, particularly molecular ones, offer new targets for characterizing diseases and for drug discovery and development.
The Asia-Pacific (APAC) clinical biomarkers market is rapidly expanding, driven by advancements in biotechnology, increased healthcare spending, and a growing focus on personalized medicine. Countries like China, Japan, and India are at the forefront, with substantial investments in research and development and robust clinical trial activities.
The rising prevalence of chronic diseases, such as cancer and cardiovascular conditions, fuels the demand for early diagnostic tools and targeted therapies. Government initiatives and collaborations between academic institutions and biopharmaceutical companies further propel market growth. The integration of advanced technologies, such as next-generation sequencing and bioinformatics, enhances the identification and validation of novel biomarkers, making the APAC region a crucial player in the clinical biomarkers landscape.
How Can This Report Add Value to an Organization?
Growth/Marketing Strategy: Product launches and upgradations accounted for the maximum number of key developments. Numerous synergistic activities, fundings, and acquisitions of the market have also been tracked during the same time period.
Competitive Strategy: The clinical biomarkers market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the Asia-Pacific clinical biomarkers market analyzed and profiled in the study involve established players that offer various kinds of products and services.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 53 |
| Forecast Period | 2023 – 2033 |
| Estimated Market Value (USD) in 2023 | $3.28 Billion |
| Forecasted Market Value (USD) by 2033 | $7.95 Billion |
| Compound Annual Growth Rate | 9.2% |
| Regions Covered | Asia Pacific |
Key Topics Covered:
Executive Summary
1 Market
2 Market Scope
2.1 Key Questions Answered in the Report
3 Research Methodology
3.1 Data Sources
3.1.1 Primary Data Source
3.1.2 Secondary Data Sources
3.1.2.1 Open Sources
3.2 Market Estimation Model
3.3 Criteria for Company Profiling
4 Market Overview
4.1 Introduction
4.2 Clinical Biomarkers Approaches in Precision Medicine
4.3 Market Size Potential for Clinical Biomarkers, 2022-2033
4.4 COVID-19 Impact on Clinical Biomarkers Market
4.4.1 COVID-19 Impact on Market Size
4.5 Market Trends
4.5.1 Integration of Artificial Intelligence in Biomarker Discovery
4.5.2 Increasing Biomarkers Usage in Precision Medicine
4.5.3 Technologies Being Used in Clinical Biomarker Testing
4.5.4 Clinical Biomarker Discovery Making Early Disease Diagnosis Possible
5 Region
5.1 Overview
5.2 Asia-Pacific
5.2.1 China
5.2.2 India
5.2.3 Japan
5.2.4 South Korea
5.2.5 Australia
5.2.6 Rest-of-Asia-Pacific
6 Market – Company Profiles
6.1 Overview
6.2 BGI
6.2.1 Company Overview
6.2.2 Role of BGI in the Clinical Biomarkers Market
6.2.3 Corporate Strategies
6.2.3.1 Product Launch
6.2.4 Analyst’s Perspective
6.3 Novogene Co., Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/pen75w
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Asia-Pacific Clinical Biomarkers Market
